Lipid-lowering drugs and cancer: an updated perspective

Pharmacol Rep. 2023 Nov 28. doi: 10.1007/s43440-023-00553-6. Online ahead of print.ABSTRACTStatins and non-statin medications used for the management of dyslipidemia have been shown to possess antitumor properties. Since the use of these drugs has steadily increased over the past decades, more knowledge is required about their relationship with cancer. Lipid-lowering agents are heterogeneous compounds; therefore, it remains to be revealed whether anticancer potential is a class effect or related to them all. Here, we reviewed the literature on the influence of lipid-lowering medications on various types of cancer during development or metastasis. We also elaborated on the underlying mechanisms associated with the anticancer effects of antihyperlipidemic agents by linking the reported in vivo and in vitro studies.PMID:38015371 | DOI:10.1007/s43440-023-00553-6

Source: Pharmacological Reports - November 28, 2023 Category: Drugs & Pharmacology Authors: Azin Alizadehasl Maryam Sadat Alavi Shabnam Boudagh Mohaddeseh Sadat Alavi Somaye Mohebi Leila Aliabadi Mahsa Akbarian Parisa Ahmadi Massimo R Mannarino Amirhossein Sahebkar Source Type: research